During the past decade, King's Daughter's Medical Center conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 22 clinical trials were completed, i.e. on average, 95.7% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 16 clinical trials were completed. i.e. 533.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "King's Daughter's Medical Center" #1 sponsor was "SWOG Cancer Research Network" with 9 trials, followed by "National Cancer Institute (NCI)" with 8 trials sponsored, "Abbott Medical Devices" with 3 trials sponsored, "Boston Scientific Corporation" with 3 trials sponsored and "ECOG-ACRIN Cancer Research Group" with 3 trials sponsored. Other sponsors include 10 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "King's Daughter's Medical Center" #1 collaborator was "National Cancer Institute (NCI)" with 13 trials as a collaborator, "Cancer and Leukemia Group B" with 3 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator, "North Central Cancer Treatment Group" with 3 trials as a collaborator and "ClinLogix. LLC" with 2 trials as a collaborator. Other collaborators include 23 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "King's Daughter's Medical Center" are "Recurrent Squamous Cell Lung Carcinoma" (7 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (6 trials), "Stage IB Lung Non-Small Cell Carcinoma AJCC v7" (4 trials), "Stage IIIA Lung Non-Small Cell Cancer AJCC v7" (4 trials) and "Coronary Artery Disease" (3 trials). Many other conditions were trialed in "King's Daughter's Medical Center" in a lesser frequency.

Most popular intervention types in "King's Daughter's Medical Center" are "Drug" (22 trials), "Other" (20 trials), "Device" (13 trials), "Biological" (9 trials) and "Procedure" (5 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (14 trials), "Docetaxel" (5 trials), "Nivolumab" (4 trials), "Paclitaxel" (4 trials) and "Quality-of-Life Assessment" (4 trials). Other intervention names were less common.

The vast majority of trials in "King's Daughter's Medical Center" are 37 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "King's Daughter's Medical Center". undefined are not yet recruiting, 7 are recruiting, 11 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 19 completed trials in King's Daughter's Medical Center, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in King's Daughter's Medical Center, 1 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 8 trials that are defined as “Not Applicable".

King's Daughter's Medical Center has several departments that took part in Clinical trials: "Cancer Resource Center at King's Daughters Medical Center" - 9 trials, "Kentucky Heart Institute / King's Daughter" - 2 trials